Cell Impact Q4 2025: Growth and expansion of the business paving the way forward

Cell Impact reported Q4/2025 net sales of SEK 1.1m (SEK 2.2m prior year) and an operating loss of SEK –65.4m (–39.7m), with loss after financial items of SEK –66.4m and EPS of SEK –0.23 (–0.56). The group held SEK 10.9m in cash at the balance sheet date (SEK 20.4m prior year) and SEK 4.9m as of 3 Feb 2026, and has launched a guaranteed rights issue to raise up to SEK 33.2m to fund further commercialization and bridge to volume production. Management highlighted progress toward initial continuous flow-plate production, a strategic cooperation with thyssenkrupp Automation Engineering and a forming-tool agreement with a leading Asian vehicle manufacturer, alongside a stated diversification of operations to reduce sector concentration.

Analysis

Market structure: Cell Impact’s update keeps it squarely as a niche supplier with patented forming tech but with acute scale risk; winners are large electrolyzer/fuel‑cell OEMs (e.g., NEL, PLUG) and Tier‑1 automation partners (thyssenkrupp) that can integrate cheaper flow‑plate supply, while small-cap suppliers and current Cell Impact shareholders face dilution and customer concentration pain. Competitive dynamics: until Cell Impact proves sustainable continuous production (watch for >500 plates/month sustained over 3 months) it cannot exert pricing power — incumbents retain bargaining leverage and could force margins down if Cell Impact cuts price to win volume.

Risk assessment: immediate risk (days–weeks) centers on the rights issue subscription outcome — cash fell to SEK 4.9m (Feb 3); failure to secure SEK33.2m pre‑costs likely leads to insolvency within 3–6 months. Tail risks include technology scale failure, loss of the Asian OEM contract, or OEM vertical integration; long‑term upside is acquisition by a Tier‑1 if tech proves scalable. Hidden dependency: heavy reliance on one customer and one cooperation partner creates single‑point operational and revenue risk.

Trade implications: avoid unhedged longs in Cell Impact until post‑rights visibility; consider a relative‑value trade long larger electrolyzer/fuel‑cell names (NEL, PLUG) vs short Cell Impact to capture consolidation/scale wins. Options: use 12‑18 month LEAP calls on NEL/PLUG (25% OTM) to play adoption, and use put spreads on Cell Impact or small‑cap peers to limit borrowing/assignment risk. Key triggers: rights issue result (2–6 weeks), monthly delivery cadence, and any firm multi‑year contracts.

Contrarian angles: the market may underprice acquisition value — patented, waterless forming tech is strategically attractive to automakers and automation firms; if rights issue restores a >SEK30m runway and the company posts confirmed multi‑year volume contracts, shares could re‑rate materially. Reaction may be both overdone (panic around dilution) and underdone (strategic M&A premium), so favor small, event‑contingent stakes rather than conviction longs today.

Key Decisions for Investors

• Do NOT initiate an unhedged long in Cell Impact AB today; if borrow is available, establish a tactical short (or buy put spread) equal to 1–2% NAV if the rights issue subscription rate is <75% or pro forma cash after the issue is <SEK25m; set a stop‑loss at a 30% adverse move.
• Establish a 2–3% position in NEL ASA (ticker NEL) via 12–18 month LEAP calls ~25% OTM (or equivalent cash position) to play electrolyzer scale; target 40–60% upside over 12 months and take profits on confirmed large OEM orders or a >20% positive revision in guidance.
• Implement a pair trade: Long NEL (2% NAV) / Short Cell Impact (1% NAV) to capture scale consolidation — rebalance or close the short if Cell Impact reports 3 consecutive months >500 plates/month and pro‑forma cash runway ≥SEK30m.
• Prepare a capped event‑driven long (0.5–1% NAV) in Cell Impact to be executed only if, post‑rights issue (within 2–6 weeks), two conditions are met: pro‑forma cash ≥SEK30m AND at least one confirmed multi‑year supply contract covering ≥50% of expected capacity; use a 50% stop‑loss to limit tail risk.